Search Results - "Kwo, P"

All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database by Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., Everson, G. T., Kwo, P. Y., Brown, R. S., Sulkowski, M. S., Akuschevich, L., Lok, A. S., Pockros, P. J., Vainorius, M., Terrault, N. A., Nelson, D. R., Fried, M. W., Manns, M. P.

“…Summary Background Chronic hepatitis C virus therapy in patients with advanced liver disease remains a clinical challenge. HCV‐TARGET collects data in patients…”
Get full text

Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma by Cárdenes, Higinia R., Price, Tracy R., Perkins, Susan M., Maluccio, Mary, Kwo, P., Breen, T. E., Henderson, Mark A., Schefter, Tracey E., Tudor, Kathy, Deluca, Jill, Johnstone, Peter A. S.

“…Background Hepatocellular carcinoma (HCC) is increasing in incidence and the majority of patients are not candidates for radical therapies. Therefore, interest…”
Get full text

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies by Kwo, P, Poordad, F, Porcalla, A, Gane, E, Lalezari, J, Wyles, D, Liu, R, Kort, J, Mensa, F.J

Get full text

Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentretreatment Protocol by Brown, R, Fried, M, Reddy, R.K, Pico, C.S, Khemichian, S, Darling, J, Napoli, A.A, Anduze-Faris, B, Kwo, P

Get full text

Radiologic Versus Pathologic Assessment of Response in Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy by Mannina, E.M, Lasley, F.D, Saxena, R, Maluccio, M, Tector, J, Kwo, P, Cardenes, H

Get full text

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study by Vierling, J.M, Sobhonslidsuk, A, Papatheodoridis, G, Assy, N, Rosenberg, W, Guyader, D, Dev, A, Gordon, S.C, Pol, S, Luketic, V.A, Khemichian, S, Evans, B, Morgan, L, Li, M, Talwani, R, Arduino, J.M, Kwo, P

Get full text

The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites by Misra, V. L., Vuppalanchi, R., Jones, D., Hamman, M., Kwo, P. Y., Kahi, C., Chalasani, N.

“…Aliment Pharmacol Ther 2010; 32: 1044–1050 Summary Background  Resistance to loop diuretics is common in patients with ascites. Diminished glomerular…”
Get full text

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection by Muir, A.J, Strasser, S, Wang, S, Shafran, S, Bonacini, M, Kwo, P, Wyles, D, Gane, E, Lovell, S.S, Lin, C.-W, Ng, T.I, Kort, J, Mensa, F.J

Get full text

Relationship of Hepatic Toxicity to Advancement of Child-Pugh Score and Overall Survival for Patients Treated With SBRT to the Liver by Lasley, F.D, Johnson, C.S, Mannina, E.M, Maluccio, M, Kwo, P, Cárdenes, H

Get full text

P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial by Kwo, P, Gane, E, Peng, C.-Y, Pearlman, B, Vireling, J, Serfaty, L, Buti, M, Shafran, S, Stryszak, P, Lin, L, Gress, J, Robertson, M, Wahl, J, Barr, E, Haber, B

Get full text

Phase I-II Trial of Stereotactic Body Radiation Therapy (SBRT) in Patients with Hepatocellular Carcinoma, Child-Pugh Class (CPC) A and B: Interim Analysis of Treatment Variables Affecting Toxicity and Outcome by Lasley, F.D, Calley, C, Perkins, S.M, Maluccio, M, Kwo, P, Cárdenes, H

Get full text

Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis by Gane, E.J, Nguyen, M, Kwo, P, Kowdley, K, Reau, N, Jacobson, I, Curry, M, Pearlman, B, Khalid, O, Everson, G, Gordon, S, Poulos, J, Sheikh, A, Bernstein, D, Yang, J.C, Stamm, L.M, An, D, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Tong, M, Tsai, N, Beavers, K.L, Rabinovitz, M, Shiffman, M, Stedman, C, Lawitz, E

Get full text

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals by Lawitz, E, Kowdley, K, Curry, M, Reau, N, Nguyen, M, Kwo, P, Jacobson, I, Tran, T.T, Nahass, R, Hinestrosa, F, Herring, R, Bennet, M, Yang, J.C, Stamm, L.M, An, Di, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Schiff, E, Davis, M, Etzkorn, K, Chung, R.T, Pound, D, Rodriguez-Torres, M, Reddy, K.R, Younes, Z, Gane, E.J

Get full text

High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin among Patients with Decompensated Cirrhosis who Underwent Liver Transplant during Participation in the Solar-1 and -2 Studies by Müllhaupt, B, Kwo, P, Agarwal, K, Duvoux, C, Durand, F, Peck-Radosavljevic, M, Yoshida, E.M, Lilly, L, Willems, B, Vargas, H, Kumar, P, Brown, R.S, Horsmans, Y, De-Oertel, S, Arterburn, S, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Terrault, N, Rizzetto, M

Get full text

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1 by Kwo, P, Gitlin, N, Nahass, R, Bernstein, D, Rojter, S, Schiff, E, Davis, M, Ruane, P.J, Younes, Z, Kalmeijer, R, Peeters, M, Lenz, O, Fevery, B, De La Rosa, G, Scott, J, Sinha, R, Witek, J

Get full text

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response by Clark, P. J., Thompson, A. J., Zhu, M., Vock, D. M., Zhu, Q., Ge, D., Patel, K., Harrison, S. A., Urban, T. J., Naggie, S., Fellay, J., Tillmann, H. L., Shianna, K., Noviello, S., Pedicone, L. D., Esteban, R., Kwo, P., Sulkowski, M. S., Afdhal, N., Albrecht, J. K., Goldstein, D. B., McHutchison, J. G., Muir, A. J.

“…Low‐density lipoprotein cholesterol (LDL‐C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to…”
Get full text

202 USE OF TELAPREVIR PLUS PEG INTERFERON/RIBAVIRIN FOR NULL RESPONDERS POST OLT WITH ADVANCED FIBROSIS/CHOLESTATIC HEPATITIS C by Kwo, P, Ghabril, M, Lacerda, M, Vinayek, R, Tector, A.J, Fridell, J, Vianna, R

Get full text

Gender differences in alcohol metabolism: Relationship to liver volume and effect of adjusting for body mass by Kwo, Paul Y., Ramchandani, Vijay A., O'Connor, Sean, Amann, Deborah, Carr, Lucinda G., Sandrasegaran, Kumar, Kopecky, Kenyon K., Li, Ting-Kai

“…Background & Aims: Alcoholic liver disease purportedly develops more readily in women than in men. Some studies have demonstrated faster rates of alcohol…”
Get full text

O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION by Kwo, P, Mantry, P, Coakley, E, Te, H, Vargas, H, Brown, R, Gordon, F, Levitsky, J, Terrault, N, Burton, J, Xie, W, Setze, C, Badri, P, Vilchez, R.A, Forns, X

Get full text

P1234 SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION by Hezode, C, Bruno, S, Jacobson, I, Serfaty, L, Kwo, P, Zhou, A, Gilbert, C, Hwang, P, Wahl, J, Robertson, M.N, Mobashery, N

Get full text